AllSci News
Ollin secures USD 330m to advance VEGF/Ang2 BsAb after beating Vabysmo head-to-head
Austin, Texas-based Ollin Biosciences, Inc. has closed an oversubscribed USD 330 million Series B financing round to fund global Phase III development of...
HHS launches Operation Trialblazer to reverse offshoring of early-phase clinical research
Category: Clinical Trial Reform | Regulatory Body: HHS | Geography: United States | Instrument: Initiative launch
Abu Dhabi opens gateway to California’s life sciences ecosystem
The Department of Health – Abu Dhabi (DoH) and Biocom California announced a strategic memorandum of understanding establishing a formal gateway between…
Lilly expands Abbisko partnership with multi-target deal worth up to USD 1.9b
Shanghai-based Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK) and Eli Lilly and Company have announced a multi-target research collaboration and license agreement under…
Definium secures USD 700m in upsized offering for psychedelic pipeline
New York-based Definium Therapeutics, Inc. (Nasdaq: DFTX) announced the pricing of an upsized underwritten public offering of common shares, raising...
Definium's LSD formulation becomes first psychedelic to beat placebo in Phase III depression trial
New York-based Definium Therapeutics (Nasdaq: DFTX) reported positive topline results from the Emerge Phase III trial of DT120 (lysergide) orally...
Merck KGaA, Versant launch Saturnus Bio in USD 50m rare cardiology venture
Saturnus Bio, a precision cardiology company founded by Versant Ventures, has launched with USD 50 million in upfront funding from Merck as part of a...
NorthLinks Bio launches with USD 34m from RA Capital to advance intranasal antiviral HEX17
Boston-based NorthLinks Bio has launched with USD 34 million in financing from RA Capital Management to advance its intranasal prophylactic antiviral...
Trace Neuroscience launches first-in-class UNC13A restoration therapy into human ALS trials
South San Francisco-based Trace Neuroscience has dosed the first patients with TRCN-1023, an antisense oligonucleotide (ASO) targeting UNC13A protein...
EU approves AbbVie’s Maviret for acute hepatitis C, expanding use beyond chronic infection
The European Commission has approved Maviret (glecaprevir/pibrentasvir) for the treatment of acute hepatitis C virus (HCV) infection, making it the only therapy…
Arrowhead adds EU approval for Redemplo in FCS
Arrowhead Pharmaceuticals (Nasdaq: ARWR) has received European Commission marketing authorization for Redemplo (plozasiran) as an adjunct to diet to reduce triglyceride levels…
Osanni Bio secures USD 190m to scale platform across ophthalmology and cardiology programs
San Francisco-based Osanni Bio LLC has closed a USD 190 million Series B financing round to advance its multi-therapeutic platform, with active programs in...
Calico’s fosigotifator gains breakthrough designation for ultra-rare disease VWM
Calico Life Sciences, the San Francisco-based Alphabet-founded research organization focused on aging and age-related diseases, announced receipt of US FDA Breakthrough Therapy…
Definium raises USD 500m to push psychedelic-derived DT120 toward psychiatric disorder approval
New York-based Definium Therapeutics, Inc. (Nasdaq: DFTX) announced a proposed underwritten public offering of USD 500 million in common shares and, to...
Manufacturing-related FDA CRL delays Achieve’s cytisinicline approval timeline into 2027
Seattle and Vancouver-based Achieve Life Sciences, Inc. (Nasdaq: ACHV) disclosed that the US FDA issued a Complete Response Letter for the New…
The AllSci Brief
Systematic R&D and deal news. Daily.